Results 71 to 80 of about 30,099 (284)

Allosteric modulation of protein oligomerization: an emerging approach to drug design [PDF]

, 2014
Many disease-related proteins are in equilibrium between different oligomeric forms. The regulation of this equilibrium plays a central role in maintaining the activity of these proteins in vitro and in vivo. Modulation of the oligomerization equilibrium
Assaf Friedler, Ronen Gabizon
core   +2 more sources

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

HIV Medicine, EarlyView.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang, Ling Chen, Jia Tang, Xiaosheng Liu, Liyuan Zheng, Fada Wang, Xin Huang, Wei Cao, Taisheng Li   +8 more
wiley   +1 more source

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS [PDF]

, 2015
Huda Taha,1 Archik Das,2 Satyajit Das1,3 1Integrated Sexual Health Service Coventry and Warwickshire Partnership NHS Trust, Coventry, 2School of Medicine, Birmingham University, Birmingham, 3Coventry University, Coventry, UK Abstract: Dolutegravir (DTG)
Das, A., Das, S., Taha, H.
core   +3 more sources

Perinatal and early infant outcomes after first‐versus second‐generation integrase strand transfer inhibitor use in pregnancy

HIV Medicine, EarlyView.
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are first‐line antiretroviral medications used in pregnancy. Pre‐clinical research suggests adverse effects in human stem cells associated with second‐ versus first‐generation INSTIs.
Rosa Balleny, Jeffrey Man Hay Wong, Terry Lee, Ari Bitnun, Isabelle Boucoiran, Jason Brophy, Jeannette Comeau, Fatima Kakkar, Athena McConnell, Laura Sauvé, Joel Singer, Alena Tse‐Chang, Deborah Money   +12 more
wiley   +1 more source

Analysis of Transmitted Resistance to Raltegravir and Selective Pressure among HIV-1-Infected Patients on a Failing HAART in São Paulo, Brazil [PDF]

, 2012
We studied the presence of primary resistance to raltegravir (RAL), natural polymorphisms, and selection pressure on HIV-1 integrase. We found a high frequency of integrase polymorphisms related to the resistance to RAL and sequence stability.
Azevedo, R. G., Diaz, R. S., Komninakis, S. V., Mantovani, N. P., Rabelato, J. T., Sanabani, S.   +5 more
core   +2 more sources

Calibration and discrimination ability of the Dat'AIDS score in people living with HIV aged 70 years and older from the Dat'AIDS cohort

HIV Medicine, EarlyView.
Abstract Objective The Dat'AIDS score was developed to predict 5‐year mortality risk in people living with HIV aged 60 and older. However, its validity in people living with HIV aged 70 years and older needed confirmation. Methods This was a multicentre prospective cohort study in the Dat'AIDS French cohort.
Abeo Mousse, Clotilde Allavena, Amandine Gagneux‐Brunon, François Raffi, Laurent Hocqueloux, Claire Genet, Madeline Pascard, Damien Jolly, Firouzé Bani‐Sadr, Lukshe Kanagaratnam, Maxime Hentzien, and The Dat'AIDS Study Group, C. Chirouze, C. Drobacheff‐Thiébaut, A. Foltzer, K. Bouiller, L. Hustache‐Mathieu, Q. Lepiller, F. Bozon, O Babre, AS. Brunel, P. Muret, E. Chevalier, C. Jacomet, H. Laurichesse, O. Lesens, M. Vidal, N. Mrozek, C. Aumeran, O. Baud, V. Corbin, E. Goncalvez, A Mirand, A brebion, C Henquell, I. Lamaury, I. Fabre, E. Curlier, R. Ouissa, C. Herrmann‐Storck, B. Tressieres, MC. Receveur, F. Boulard, C. Daniel, C. Clavel, PM. Roger, S. Markowicz, N. Chellum Rungen, D. Merrien, P. Perré, T. Guimard, O. Bollangier, S. Leautez, M. Morrier, L. Laine, D. Boucher, P. Point, L. Cotte, F. Ader, A. Becker, A. Boibieux, C. Brochier, F Brunel‐Dalmas, O. Cannesson, P. Chiarello, C. Chidiac, S. Degroodt, T. Ferry, M. Godinot, J.M. Livrozet, D. Makhloufi, P. Miailhes, T. Perpoint, M. Perry, C. Pouderoux, S. Roux, C. Triffault‐Fillit, F. Valour, C. Charre, V. Icard, J.C. Tardy, M.A. Trabaud, I. Ravaux, A. Ménard, AY. Belkhir, P. Colson, C. Dhiver, A. Madrid, M. Martin‐Degioanni, L. Meddeb, M. Mokhtari, A. Motte, A. Raoux, C. Toméi, H. Tissot‐Dupont, I. Poizot‐Martin, S. Brégigeon, O. Zaegel‐Faucher, V. Obry‐Roguet, H Laroche, M. Orticoni, M.J. Soavi, E. Ressiot, M.J. Ducassou, I. Jaquet, S. Galie, H. Colson, A.S. Ritleng, A. Ivanova, C. Debreux, C. Lions, T Rojas‐Rojas, A. Cabié, S. Abel, J. Bavay, B. Bigeard, O. Cabras, L. Cuzin, R. Dupin de Majoubert, L. Fagour, K. Guitteaud, A. Marquise, F. Najioullah, S. Pierre‐François, J. Pasquier, P. Richard, K. Rome, JM Turmel, C. Varache, N. Atoui, M. Bistoquet, E Delaporte, V. Le Moing, A. Makinson, N. Meftah, C. Merle de Boever, B. Montes, A. Montoya Ferrer, E. Tuaillon, J. Reynes, B. Lefèvre, E. Jeanmaire, S. Hénard, E. Frentiu, A. Charmillon, A. Legoff, N. Tissot, M. André, L. Boyer, MP. Bouillon, M. Delestan, F. Goehringer, S. Bevilacqua, C. Rabaud, T. May, F. Raffi, C. Allavena, E. Billaud, C. Biron, B. Bonnet, S. Bouchez, D. Boutoille, C. Brunet‐Cartier, C. Deschanvres, B.J. Gaborit, M. Grégoire, O. Grossi, T. Jovelin, M. Lefebvre, P. Le Turnier, R. Lecomte, P. Morineau, V. Reliquet, S. Sécher, M. Cavellec, E. Paredes, A. Soria, V. Ferré, E. André‐Garnier, A. Rodallec, P. Pugliese, S. Breaud, C. Ceppi, D. Chirio, E. Cua, P. Dellamonica, E. Demonchy, A. De Monte, J. Durant, C. Etienne, S. Ferrando, R. Garraffo, C. Michelangeli, V. Mondain, A. Naqvi, N. Oran, I. Perbost, M. Carles, C. Klotz, A. Maka, C. Pradier, B. Prouvost‐Keller, K. Risso, V. Rio, E. Rosenthal, I. Touitou, S. Wehrlen‐Pugliese, G. Zouzou, L. Hocqueloux, C.Mille. T. Prazuck, C. Gubavu, A. Sève, G. Béraud, V. Legros, V. Avettand‐Fènoël, A. Cheret, C. Goujard, Y. Quertainmont, E. Teicher, N. Lerolle, S. Jaureguiberry, R. Colarino, O. Deradji, A. Castro, A. Barrail‐Tran, Y. Yazdanpanah, R. Landman, V. Joly, J. Ghosn, C. Rioux, S. Lariven, A. Gervais, FX. Lescure, S. Matheron, F. Louni, Z. Julia, S. Le GAC C. Charpentier, D. Descamps, G. Peytavin, C. Duvivier, C. Aguilar, F. Alby‐Laurent, K. Amazzough, G. Benabdelmoumen, P. Bossi, G. Cessot, C. Charlier, P.H. Consigny, K. Jidar, E. Lafont, F. Lanternier, J. Leporrier, O. Lortholary, C. Louisin, J. Lourenco, P. Parize, B. Pilmis, C. Rouzaud, F. Touam, MA. Valantin, R. Tubiana, R. Agher, S. Seang, L. Schneider, R. PaLich, C. Blanc, C. Katlama, F. Bani‐Sadr, M. Hentzien, A. Brunet, D. Lambert, C. Strady, M. Moutel, M. Petithomme‐Nanrocki, V. Greigert, I. Kmiec, H. Marty, V. Brodard, C. Arvieux, P. Tattevin, M. Revest, F. Souala, M. Baldeyrou, S. Patrat‐Delon, J.M. Chapplain, F. Benezit, M. Dupont, M. Poinot, A. Maillard, C. Pronier, F. Lemaitre, C. Morlat, M. Poisson‐Vannier, T. Jovelin, JP. Sinteff, A. Gagneux‐Brunon, E. Botelho‐Nevers, A. Frésard, V. Ronat, F. Lucht, D. Rey, P. Fischer, M. Partisani, C. Cheneau, C. Mélounou, C. Bernard‐Henry, E. de Mautort, S. Fafi‐Kremer, P. Delobel, M. Alvarez, N. Biezunski, A. Debard, C. Delpierre, G. Gaube, P. Lansalot, L. Lelièvre, M. Marcel, G. Martin‐Blondel, M. Piffaut, L. Porte, K. Saune, O. Robineau, F. Ajana, E. Aïssi, I. Alcaraz, E. Alidjinou, V. Baclet, L. Bocket, A. Boucher, M. Digumber, T. Huleux, B. Lafon‐Desmurs, A. Meybeck, M. Pradier, M. Tetart, P. Thill, N. Viget, M. Valette   +337 more
wiley   +1 more source

Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors

Scientific Reports
Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these
Mhairi J. McCormack, Patawee Asamaphan, Ellen C. Hughes, Louis Banda, Stephen Kasenda, Chris Davis, Agnieszka M. Szemiel, Amelia Crampin, Abena S. Amoah, Emma C. Thomson, Antonia Ho, Brian J. Willett   +11 more
doaj   +1 more source

Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening

Molecules, 2019
Currently, an increasing number of drugs are becoming available to clinics for the treatment of HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in ...
Cindy Aknin, Elena A. Smith, Christophe Marchand, Marie-Line Andreola, Yves Pommier, Mathieu Metifiot   +5 more
doaj   +1 more source

Investigation of furo[2,3-h]- and pyridazino[3,4-f]cinnolin-3-ol scaffolds as substrates for the development of novel HIV-1 integrase inhibitors [PDF]

, 2011
With the aim to develop novel HIV-1 integrase inhibitors, we obtained a set of condensed ring systems based on the furo[2,3-h]cinnolin-3(2H)-one and pyridazino[3,4-f]cinnolin-3-ol scaffolds bearing a potential chelating pharmacophore, which can be ...
Casule, Paola, Derudas, Marco, El-Tamany, El-Sayed H, Gomaa, Mohamed F Y, Hasanen, Jehan Abd-Elrazik, Mariani, Alberto, Pala, Nicolino, Sechi, Mario   +7 more
core   +1 more source

Treatment durability, satisfaction and quality of life in virologically suppressed HIV‐1 people switching to doravirine: Results from the French study DoraVIH

HIV Medicine, EarlyView.
Abstract Objectives In Europe, most people with HIV‐1(PWH) achieve virologic suppression with effective and well‐tolerated antiretroviral therapies (ART). In this context, patient‐reported outcomes (PRO) are increasingly important for evaluating ART benefits.
Spire Bruno, Robineau Olivier, Pourcher Valérie, Loubet Paul, Palacios Christia, Jacomet Christine, Benachir Haydar, Mariot Philippe, Parienti Jean‐Jacques, Slama Laurence   +9 more
wiley   +1 more source